CFM
NBIX icon

Catalyst Funds Management’s Neurocrine Biosciences NBIX Stock Holding History

Catalyst Funds Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438K Buy
+2,600
New +$386K 0.02% 418
2024
Q3 		– Sell
-1,700
Closed -$234K – 1502
2024
Q2 		$234K Buy
+1,700
New +$233K 0.06% 190

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Catalyst Funds Management's NBIX Position: Q2 2026 in Review

Catalyst Funds Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 2,600 shares worth $438K. The stake represents 0.02% of the portfolio and ranks #418 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in NBIX as recently as Q2 2024.

Catalyst Funds Management first reported a position in NBIX in Q2 2024 and has held it in 2 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Catalyst Funds Management held 2,600 shares of Neurocrine Biosciences worth $438K as of Q2 2026.
  • Neurocrine Biosciences was a new Catalyst Funds Management position in Q2 2026.
  • Neurocrine Biosciences made up 0.02% of Catalyst Funds Management's portfolio in Q2 2026, its #418 holding.
  • Catalyst Funds Management first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 2 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.